The transcription factor c-Myc is frequently dysregulated in hematological malignancies, especially in a large proportion of aggressive B cell lymphomas such as Burkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL). Here, MYC is linked to B-cell non-Hodgkin lymphoma.